Video

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non—small cell lung cancer (NSCLC).

In the treatment of this oncogene-driven subset, it seems that the standard initial therapy is with the third-generation tyrosine kinase inhibitor osimertinib (Tagrisso). This agent was granted a second FDA indication in April 2018 for the frontline treatment of patients whose tumors harbor EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations). In terms of progression-free survival, sequential therapy might work just as well, but Camidge argues that a patient would likely rather take 1 oral drug.

This opens the doors to the next steps in research. Ongoing trials are looking at osimertinib in combination with antiangiogenic agents like bevacizumab (Avastin) or with chemotherapy. However, Camidge says the more pressing question is why patients become resistant to osimertinib, and then developing rational combinations to overcome this.

Related Videos
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD